## Edgar Filing: Horizon Pharma plc - Form 4

| Form 4  | ŕ                                       |               |                   |   |            |                         |                         |   |  |              |   |  |
|---|---|---------------|-------------------|---|------------|-------------------------|-------------------------|---|--|--------------|---|--|
| March 24, 2016<br>FORM 4<br>UNITED STATES SECURITIES AND EXCHANGE CO<br>Washington, D.C. 20549  |   |               |                   |   | COMMISSION | OMB A<br>OMB<br>Number: | PPROVAL<br>3235-0287    |   |  |              |   |  |
| subject to<br>subject to<br>Section 16.<br>Form 4 or<br>Form 5<br>obligations<br>may continue.<br>See Instruction<br>1(b).<br>StateMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF<br>SECURITIES<br>Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,<br>Section 17(a) of the Public Utility Holding Company Act of 1935 or Section<br>30(h) of the Investment Company Act of 1940 |   |               |                   |   |            |                         |                         | burden hou<br>response  | ted average<br>hours per   |              |   |  |
| Carey Robert Sy   |   |               |                   |   |            | d Ticker or<br>plc [HZ] |                         | ng  | 5. Relationship of Reporting Person(s) to<br>Issuer<br>(Check all applicable)  |              |   |  |
| (Mor  |   |               |                   | ate of Earliest Transaction<br>nth/Day/Year)<br>23/2016   |            |                         |                         |   | Director 10% Owner<br>X Officer (give title Other (specify<br>below) below)<br>EVP, Chief Business Officer                                       |              |   |  |
| (Street) 4. If Am   |   |               |                   | nendment, Date Original<br>onth/Day/Year)   |            |                         |                         |   | 6. Individual or Joint/Group Filing(Check<br>Applicable Line)<br>_X_ Form filed by One Reporting Person<br>Form filed by More than One Reporting |              |   |  |
| (City)  | (State)                                 | (Zip)         | Tah               | le I - No   | on-I       | Derivative              | Secur                   | ities Aco   | Person   | or Beneficia | llv Owned   |  |
| 1.Title of<br>Security<br>(Instr. 3)  | 2. Transaction Date<br>(Month/Day/Year) | Execution any | ned<br>1 Date, if | Transactior(A) or Disposed of (D) Sec<br>Code (Instr. 3, 4 and 5) Ben<br>(Instr. 8) Ow<br>Foll<br>(A) Tran<br>or (Instr. 4) |            |                         | 5. Amount of Securities | 6.<br>Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) | 7. Nature of<br>Indirect   |              |   |  |
| Ordinary<br>Shares  | 03/23/2016                              |               |                   | Code<br>M   | V          | Amount 31,000           | (D)<br>A                | Price<br>( <u>1)</u>  |  | D            |   |  |
| Ordinary<br>Shares  | 03/23/2016                              |               |                   | F   |            | 14,167                  | D                       | \$<br>16.32   | 38,242   | D            |   |  |
| Ordinary<br>Shares  |   |               |                   |   |            |                         |                         |   | 82,061   | I            | By Robert<br>F. Carey III<br>Trust dated<br>4/24/2001 |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | 5. Number of<br>orDerivative<br>Securities<br>Acquired (A)<br>or Disposed o<br>(D)<br>(Instr. 3, 4,<br>and 5) | vative Expiration Date<br>rities (Month/Day/Year)<br>uired (A)<br>isposed of<br>r. 3, 4, |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |                                     | 8. F<br>Der<br>Sec<br>(Ins |
|---|---|---|---|--|---|--|--------------------|---|-------------------------------------|----------------------------|
|   |   |   |   | Code V                                 | (A) (D)   | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of Shares |                            |
| Restricted<br>Stock<br>Units                        | <u>(1)</u>  | 03/23/2016                              |   | М                                      | 31,000  | (2)  | (2)                | Ordinary<br>Shares  | 31,000                              |                            |

## **Reporting Owners**

| Reporting Owner Name / Address  |            | Relationships |         |                             |  |  |  |  |
|---|------------|---------------|---------|-----------------------------|--|--|--|--|
|   | Director   | 10% Owner     | Officer | Other                       |  |  |  |  |
| Carey Robert<br>C/O HORIZON PHARMA PLC<br>CONNAUGHT HOUSE, 1ST FL, 1 BURLIN<br>RD<br>DUBLIN, L2 4 | NGTON      |               |         | EVP, Chief Business Officer |  |  |  |  |
| Signatures  |            |               |         |                             |  |  |  |  |
| /s/ Paul W. Hoelscher,<br>Attorney-in-Fact  | 03/24/2016 |               |         |                             |  |  |  |  |
| **Signature of Reporting Person   | Date       |               |         |                             |  |  |  |  |

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- (2) On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.